Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus Phesgo maintenance after first-line induction in PIK3CA-mutated HER2-positive advanced breast cancer
2022-502046-28-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of inavolisib and trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Investigator-assessed progression-free survival. Planned start Jun 2023; status: authorised.
02
Drugs
inavolisibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-502046-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502046-28-00.